Global Recombinant Vaccine Market Insights Forecasts to 2033

• The Global Recombinant Vaccine Market Size was Valued at USD 8.2 Billion in 2023.
• The Market Size is Growing at a CAGR of 11.75% from 2023 to 2033.
• The Worldwide Recombinant Vaccine Market Size is expected to Reach USD 24.9 Billion by 2033.
• Asia-Pacific is expected to Grow the fastest during the forecast period.

The Global Recombinant Vaccine Market Size is expected to Reach USD 24.9 Billion by 2033, at a CAGR of 11.75% during the forecast period 2023 to 2033.

A recombinant vaccine is produced by recombinant DNA technology that involves the insertion of desired antigen-containing gene such as bacterial surface protein into a viral vector. When administered, it potentiates host antigen-specific immune responses as like natural infections. Expression of the desired antigen inside the host cell, triggers T-cells against the particular immunogen. The Hepatitis B vaccine is an example of a recombinant protein vaccine, produced by hepatitis B surface antigen (HBsAg) in yeast cells. HPV (Human papillomaviruses) is another example of a recombinant vaccine against HPVs. The rising number of technical advanced devices, regulatory approvals, and prevalence of infectious diseases are responsible for the growth of the market. The rising government initiatives for using recombinant vaccines in North America, Europe, Latin America and Asia-Pacific region are fueling the growth of the recombinant vaccines market. However factors such as high cost of vaccines, risk factors adverse effects like sore throat irritability, and strict regulatory policies hinder the market. The advancement in the cell culture medium and improvement in the bioreactor design results into the development and production of new and more effective vaccines for human and animal health.

Report Coverage

This research report categorizes the market for global recombinant vaccine market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global recombinant vaccine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the global recombinant vaccine market.

Driving Factors

The rise in R&D activities and advancements in technologies, augment the development and growth opportunities of recombinant vaccines. Furthermore, the increasing prevalence of infectious diseases, escalating the vaccination rates worldwide. The rising product approvals creates lucrative opportunities for the global recombinant vaccine market during the forecast period. The development of mRNA technology-based vaccine is driving the market growth of global recombinant vaccine.

Restraining Factors        

Refrigeration of vaccine account for about 80% of the vaccination price as it is a costly process, thus rising vaccination cost, result into limiting the market growth.  Additionally, factors such as adverse effects of vaccines and strict regulatory policies hinder the market.

Market Segmentation

The Global recombinant vaccine as a service Market share is classified into Type, Diseases, End-user, and Regional insights

By Type Insights

• The subunit recombinant vaccines segment dominates the market with the largest revenue share over the forecast period.

On the basis of type, the global recombinant vaccines market is segmented into subunit recombinant vaccine, attenuated recombinant vaccines and vector recombinant vaccines. Among these, the subunit recombinant vaccine segment is dominating the market with the largest revenue share over the forecast period. Recombinant subunit vaccines doesn’t contain live component of pathogenic virus, thus shielding risk of disease. Therefore, it is safer and more stable than other type of vaccine.

By Diseases Insights

• The hepatitis B segment is witnessing significant CAGR growth over the forecast period.

On the basis of diseases, the global recombinant vaccine market is segmented into pneumococcal, cancer, hepatitis B, influenza, DPT and others. Among these, the hepatitis B segment is witnessing significant growth over the forecast period. The increasing prevalence of hepatitis B in developing and underdeveloped countries, accelerating the demand of hepatitis B vaccines.

By End-user

• The adult segment is witnessing significant CAGR growth over the forecast period.

On the basis of end-user, the global recombinant vaccine market is segmented into pediatrics and adults. Among these, the adults segment is witnessing significant growth over the forecast period. The upsurge in the number of adult patients suffering from chronic diseases escalates the growth of recombinant vaccine market.

Regional Insights

• North America dominates the market with the largest market share over the forecast period.

North America is dominating the market with the largest market share over the forecast period. North America has a high prevalence rate of chronic diseases, there is an increase in the number of market players that surge to enhance the vaccination rates in the region. In U.S., there is high prevalence of various infections such as Ebola, Zika, and influenza, that is increasing R&D activities of recombinant vaccine.   

Asia-Pacific is expected to grow the fastest during the forecast period. Since, Asia-pacific has highly populated countries such as India and China, there is high prevalence rate of infectious diseases, thus increasing number of product launch and other trends adopted by the market players.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global recombinant vaccine market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market

List of Key Market Players

• AstraZeneca Plc.
• Dynavax Technologies Corporation
• Johnson & Johnson
• Merck & Co. Inc.
• Novovax, Inc.,
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Abiomed
• Emergent Bio Solutions, Inc.
• GlaxoSmithKline
• Johnson & Johnson
• Sanofi Pasteur SA
• Serum Institute of India Pvt. Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Daiichi Sankyo
• Pifzer, Inc.
• Others

Key Market Developments

• In April 2022, Candila Pharma launched three-dose rabies vaccine. ThRabis is developed using Virus-Like Particle technology and priced at Rs.715 per dose. It is a novel recombinant nano-particle based rabies G protein vaccine that is administered via intramuscular injection, thus is less painful than other parenteral route of administration.

• In June 2021, six-in-one Pediatric vaccine from Merck, Sanofi available across US. The pediatric vaccine named as Vaxelis from Merck and Sanofi is the only hexavalent combination vaccine available in the US and is indicated for active immunization to help prevent six diseases (diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease caused by Hemophilus influenza type b).

• In September 2021, Serum Insitute of India to supply inactivated Polio Vaccine (IPV) to centre for Universal Immunisation Programme from September. The IPV of Serum Institute of India is WHO pre-qualified for supplies to various countries worldwide also.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2032. Spherical Insights has segmented the global Recombinant vaccine market based on the below-mentioned segments:

Recombinant Vaccine Market, Type Analysis

• Subunit Recombinant Vaccine
• Attenuated Recombinant Vaccines
• Vector Recombinant Vaccines

Recombinant Vaccine Market, Disease Analysis

•  Pneumococcal
• Cancer
• Hepatitis B
• Influenza
• DPT
• Others

Recombinant Vaccine Market, End-user Analysis

•  Pediatrics
•  Adult

Recombinant Vaccine Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa